抑制星形胶质细胞甘氨酸转运体-1：改善NMDA受体功能低下的助力还是阻力？ - Suppr

Suppr

超能文献

Inhibition of astrocytic glycine transporter-1: friend or foe for ameliorating NMDA receptor hypofunction?

作者信息

Singer Philipp, Yee Benjamin K

机构信息

Roche Diagnostics International AG, Rotkreuz, Switzerland.

Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR, China.

出版信息

Front Cell Neurosci. 2024 May 24;18:1389718. doi: 10.3389/fncel.2024.1389718. eCollection 2024.

DOI:10.3389/fncel.2024.1389718

PMID:38854433

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11158624/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf6b/11158624/46206d30ab81/fncel-18-1389718-g0001.jpg

相似文献

Inhibition of astrocytic glycine transporter-1: friend or foe for ameliorating NMDA receptor hypofunction?

Front Cell Neurosci. 2024 May 24;18:1389718. doi: 10.3389/fncel.2024.1389718. eCollection 2024.

Glycine transport inhibitors for the treatment of schizophrenia.

Open Med Chem J. 2010 May 27;4:10-9. doi: 10.2174/1874104501004010010.

Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?

Curr Pharm Des. 2015;21(26):3771-87. doi: 10.2174/1381612821666150724100952.

Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile.

J Neurosci. 2006 Mar 22;26(12):3169-81. doi: 10.1523/JNEUROSCI.5120-05.2006.

Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity.

J Neurosci. 2002 Aug 1;22(15):6713-23. doi: 10.1523/JNEUROSCI.22-15-06713.2002.

Glycine transporter inhibitors as therapeutic agents for schizophrenia.

Recent Pat CNS Drug Discov. 2006 Jan;1(1):43-53. doi: 10.2174/157488906775245336.

Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia.

Pharmacol Ther. 2008 Dec;120(3):317-32. doi: 10.1016/j.pharmthera.2008.08.004. Epub 2008 Aug 27.

Glycine transporter-1: a new potential therapeutic target for schizophrenia.

Curr Pharm Des. 2011;17(2):112-20. doi: 10.2174/138161211795049598.

Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats.

Behav Brain Res. 2015 Feb 1;278:186-92. doi: 10.1016/j.bbr.2014.09.046. Epub 2014 Oct 6.

D-alanine added to antipsychotics for the treatment of schizophrenia.

Biol Psychiatry. 2006 Feb 1;59(3):230-4. doi: 10.1016/j.biopsych.2005.06.032. Epub 2005 Sep 9.

引用本文的文献

Differential Astrocyte-Supplied NMDAR Co-Agonist for CA1 Versus Dentate Gyrus Long-Term Potentiation.

Hippocampus. 2025 Sep;35(5):e70029. doi: 10.1002/hipo.70029.

本文引用的文献

Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia.

Eur Arch Psychiatry Clin Neurosci. 2023 Oct;273(7):1557-1566. doi: 10.1007/s00406-023-01576-z. Epub 2023 Mar 27.

Glycine transporters in schizophrenia. A new hope or informational noise?

Psychiatr Pol. 2022 Apr 30;56(2):217-228. doi: 10.12740/PP/OnlineFirst/126661.

Metabotropic Glutamate Receptors As Emerging Targets for the Treatment of Schizophrenia.

Mol Pharmacol. 2022 May;101(5):275-285. doi: 10.1124/molpharm.121.000460. Epub 2022 Mar 3.

Directly and Indirectly Targeting the Glycine Modulatory Site to Modulate NMDA Receptor Function to Address Unmet Medical Needs of Patients With Schizophrenia.

Front Psychiatry. 2021 Oct 1;12:742058. doi: 10.3389/fpsyt.2021.742058. eCollection 2021.

Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study.

Lancet Psychiatry. 2021 Mar;8(3):191-201. doi: 10.1016/S2215-0366(20)30513-7.

Fifty Years of Research on Schizophrenia: The Ascendance of the Glutamatergic Synapse.

Am J Psychiatry. 2020 Dec 1;177(12):1119-1128. doi: 10.1176/appi.ajp.2020.20101481.

The NMDA receptor activation by d-serine and glycine is controlled by an astrocytic Phgdh-dependent serine shuttle.

Proc Natl Acad Sci U S A. 2019 Oct 8;116(41):20736-20742. doi: 10.1073/pnas.1909458116. Epub 2019 Sep 23.

Glycine Transporter Type I (GlyT1) Inhibitor, Bitopertin: A Journey from Lab to Patient.

Chimia (Aarau). 2018 Aug 22;72(7):477-484. doi: 10.2533/chimia.2018.477.

Glycinergic signaling in the human nervous system: An overview of therapeutic drug targets and clinical effects.

Ment Health Clin. 2016 Nov 3;6(6):266-276. doi: 10.9740/mhc.2016.11.266. eCollection 2016 Nov.

Glycine transporter-1 inhibitors: a patent review (2011-2016).

Expert Opin Ther Pat. 2018 Mar;28(3):197-210. doi: 10.1080/13543776.2018.1429408. Epub 2018 Jan 24.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Inhibition of astrocytic glycine transporter-1: friend or foe for ameliorating NMDA receptor hypofunction?

作者信息

Singer Philipp, Yee Benjamin K

机构信息

Roche Diagnostics International AG, Rotkreuz, Switzerland.

Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR, China.

出版信息

Front Cell Neurosci. 2024 May 24;18:1389718. doi: 10.3389/fncel.2024.1389718. eCollection 2024.

DOI:10.3389/fncel.2024.1389718

PMID:38854433

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11158624/

Abstract

摘要

相似文献

Inhibition of astrocytic glycine transporter-1: friend or foe for ameliorating NMDA receptor hypofunction?

Front Cell Neurosci. 2024 May 24;18:1389718. doi: 10.3389/fncel.2024.1389718. eCollection 2024.

Glycine transport inhibitors for the treatment of schizophrenia.

Open Med Chem J. 2010 May 27;4:10-9. doi: 10.2174/1874104501004010010.

Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?

Curr Pharm Des. 2015;21(26):3771-87. doi: 10.2174/1381612821666150724100952.

Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile.

J Neurosci. 2006 Mar 22;26(12):3169-81. doi: 10.1523/JNEUROSCI.5120-05.2006.

Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity.

J Neurosci. 2002 Aug 1;22(15):6713-23. doi: 10.1523/JNEUROSCI.22-15-06713.2002.

Glycine transporter inhibitors as therapeutic agents for schizophrenia.

Recent Pat CNS Drug Discov. 2006 Jan;1(1):43-53. doi: 10.2174/157488906775245336.

Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia.

Pharmacol Ther. 2008 Dec;120(3):317-32. doi: 10.1016/j.pharmthera.2008.08.004. Epub 2008 Aug 27.

Glycine transporter-1: a new potential therapeutic target for schizophrenia.

Curr Pharm Des. 2011;17(2):112-20. doi: 10.2174/138161211795049598.

Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats.

Behav Brain Res. 2015 Feb 1;278:186-92. doi: 10.1016/j.bbr.2014.09.046. Epub 2014 Oct 6.

D-alanine added to antipsychotics for the treatment of schizophrenia.

Biol Psychiatry. 2006 Feb 1;59(3):230-4. doi: 10.1016/j.biopsych.2005.06.032. Epub 2005 Sep 9.

引用本文的文献

Differential Astrocyte-Supplied NMDAR Co-Agonist for CA1 Versus Dentate Gyrus Long-Term Potentiation.

Hippocampus. 2025 Sep;35(5):e70029. doi: 10.1002/hipo.70029.

本文引用的文献

Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia.

Eur Arch Psychiatry Clin Neurosci. 2023 Oct;273(7):1557-1566. doi: 10.1007/s00406-023-01576-z. Epub 2023 Mar 27.

Glycine transporters in schizophrenia. A new hope or informational noise?

Psychiatr Pol. 2022 Apr 30;56(2):217-228. doi: 10.12740/PP/OnlineFirst/126661.

Metabotropic Glutamate Receptors As Emerging Targets for the Treatment of Schizophrenia.

Mol Pharmacol. 2022 May;101(5):275-285. doi: 10.1124/molpharm.121.000460. Epub 2022 Mar 3.

Directly and Indirectly Targeting the Glycine Modulatory Site to Modulate NMDA Receptor Function to Address Unmet Medical Needs of Patients With Schizophrenia.

Front Psychiatry. 2021 Oct 1;12:742058. doi: 10.3389/fpsyt.2021.742058. eCollection 2021.

Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study.

Lancet Psychiatry. 2021 Mar;8(3):191-201. doi: 10.1016/S2215-0366(20)30513-7.

Fifty Years of Research on Schizophrenia: The Ascendance of the Glutamatergic Synapse.

Am J Psychiatry. 2020 Dec 1;177(12):1119-1128. doi: 10.1176/appi.ajp.2020.20101481.

The NMDA receptor activation by d-serine and glycine is controlled by an astrocytic Phgdh-dependent serine shuttle.

Proc Natl Acad Sci U S A. 2019 Oct 8;116(41):20736-20742. doi: 10.1073/pnas.1909458116. Epub 2019 Sep 23.

Glycine Transporter Type I (GlyT1) Inhibitor, Bitopertin: A Journey from Lab to Patient.

Chimia (Aarau). 2018 Aug 22;72(7):477-484. doi: 10.2533/chimia.2018.477.

Glycinergic signaling in the human nervous system: An overview of therapeutic drug targets and clinical effects.

Ment Health Clin. 2016 Nov 3;6(6):266-276. doi: 10.9740/mhc.2016.11.266. eCollection 2016 Nov.

Glycine transporter-1 inhibitors: a patent review (2011-2016).

Expert Opin Ther Pat. 2018 Mar;28(3):197-210. doi: 10.1080/13543776.2018.1429408. Epub 2018 Jan 24.